(MedPage Today) -- Media headlines recently cheered on HHS Secretary Robert F. Kennedy Jr.'s announcement of a "Quality and Safety Special Alert" from the Centers for Medicare & Medicaid Services (CMS) directing hospitals to implement the new...
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Good morning health tech readers!
Today, a deep dive into why America’s most powerful health insurer is looking more and more like a technology company.
Continue to STAT+ to read the full story…
© Tim Gruber for STAT
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
The 2026 STAT Madness competition was stacked with research on topics like smart dental floss that monitors stress, Baby KJ’s personalized gene therapy, and an artificial intelligence model designed to predict cell behavior. Check out the winner, unveiled this morning. And as always, send news tips to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.
The 2027 budget that the Trump administration released on Friday is in many ways a repeat of last year’s proposal: It includes deep cuts to the National Institutes of Health, the elimination of a health research agency, and the creation of a new agency devoted to chronic diseases called the Administration for a Healthy America.
Continue to STAT+ to read the full story…
© Adobe
For some advanced cancers, sequencing the tumor genome should be one of the first steps patients and physicians take. But a new study finds that many patients never receive genomic testing and so never get the chance to know if they might have benefitted from newer, more targeted therapies.
The study, published on Tuesday in JAMA Network Open, examined how many patients diagnosed with one of five different metastatic cancers received genetic sequencing for the cancers. For most cancers in the study, roughly half of patients in the cohort received genetic sequencing. Patients with low income, Medicare or Medicaid coverage, and Black or Hispanic race or ethnicity were also less likely to receive sequencing.
Cancer medicine and research have made enormous progress over the last few decades. The overall five-year survival rate has pushed up to 70% as of 2026, and the five-year survival rate for metastatic cancer has doubled since the 1960s. That’s in large part thanks to advances in medicines and technologies that can help treat cancer, like targeted therapies that work by exploiting key cancer mutations.
Continue to STAT+ to read the full story…
© Ewa Krawczyk/National Cancer Institute via AP
Exciting times are ahead in the world of enterprise perimeter security with a new partnership between Thrive Logic, an AI agent-driven security and operational intelligence platform, and Asylon, a security robotics company. Together, the companies are to introduce physical AI into the network edge security arena, combining “autonomous perimeter patrols with agentic AI analytics and automated incident workflows.” The goal is to reduce response friction and let security leaders report with confidence in high-security exterior zones.
Physical AI understands real-world situations and is capable of responding actively via a continuous, mobile security presence. This is in comparison to merely recording events as and when they take place, for actions to happen later.
Using Asylon’s robotic patrols and Thrive Logic’s AI agent, the integration will monitor perimeter areas and analyse any incidents that may occur. Security teams might therefore relax a little and let AI detect issues in real time. In this arena, it could soon be ‘AI – 1, Bad Actors – 0.’
With pressure rising on security leaders in perimeter-intensive environments (labour volatility and unreliable patrol executions are two examples that spring to mind), Asylon’s Robotic Security Operations Centre (RSOC) helps combat challenges with audit-read security outcomes. Alongside Thrive Logic’s integration, robotic patrols won’t just collect video streams, but will produce alerts and step-by-step response processes. Therefore, security teams can respond more effectively, proving humans and AI can work in harmony.
Video captured by Asylon’s robotic patrols is securely sent to Thrive Logic’s platform. From here, the Thrive Logic AI agent continues to track connected streams, triggering alerts to relevant staff and stakeholders, and generating automated incident workflows aligned to SOP if or when these are required.
The system allows enterprise security organisations to reduces operational friction, and see improvements in response consistency. The system will generate audit-ready, time-stamped incident records for all sites where the technology operates.
Damon Henry, CEO of Asylon Robotics, said: “Security leaders don’t need more dashboards – they need reliable coverage, consistent response, and defensible reporting. Robotic systems that extend perimeter presence, paired with AI that turns what’s observed into clear actions and documented outcomes. By integrating Asylon’s RSOC-managed robotic patrols with Thrive Logic’s agentic AI analytics and incident workflow automation, we’re giving enterprise teams a practical, scalable way to reduce response friction and elevate operational maturity across sites.”
Nate Green, CEO of Thrive Logic, also emphasised the importance of physical AI. “Physical AI is where security becomes truly operational – persistent real-world visibility paired with intelligence that drives action,” he said. “Asylon’s robotic patrols create a high-value mobile layer across large perimeters. When connected to Thrive Logic’s AI agent and workflow automation, that visibility becomes actionable alerts, guided response, and audit-ready documentation.”
You may have to wait your turn to experience the Asylon-Thrive Logic Physical AI integration as it’s currently only available for enterprise security teams managing high-activity exterior environments, but the companies are hoping for greater availability to all business sizes in the near future.
(Image by ikrzeus style from Pixabay)
Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and co-located with other leading technology events. Click here for more information.
AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.
The post Asylon and Thrive Logic bring physical AI to enterprise perimeter security appeared first on AI News.
(MedPage Today) -- Contemporary external beam radiation therapy (EBRT) techniques appear to have reduced the risk of cardiovascular disease (CVD) among women with left-sided breast cancer, a large retrospective cohort study suggested.
Among women...
(MedPage Today) -- Note that some links may require registration or subscription.
An interventional cardiologist who was fired filed a lawsuit against UPMC, alleging retaliation and violation of Pennsylvania's Whistleblower Act after he reported...
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and comfortable breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is ginger peach. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
The U.S. Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs, STAT notes. FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers. The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. One of the legislative proposals in the FDA’s budget justification would let domestic manufacturers of generic drugs challenge brand drug patents a month before foreign companies, a major advantage in an intensely competitive process.
Two more drugmakers, AbbVie and Genentech, will officially start selling their medicines on the TrumpRx website, CBS News tells us. Abbvie, which struck a deal with the Trump administration in January to cut the cost of certain medicines, will sell Humira, a popular medication used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, on the site at an 86% discount. The prescription prices on the site, however, are only available to patients who are uninsured, or whose insurance does not cover it, and who must pay the full list price out of pocket. Those with insurance coverage generally pay lower prices already. TrumpRx now sells over 61 drugs at a lower price, up from about 40 when the website went live in February.
Continue to STAT+ to read the full story…
© Alex Hogan/STAT
(MedPage Today) -- The average pay increase for Medicare Advantage (MA) plans in 2027 will be 2.48%, a substantial increase from the 0.09% that the Centers for Medicare & Medicaid Services (CMS) originally proposed in January, agency officials...
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning. Amid all the tasks that demand to be addressed each day, are you having trouble finding your sense of wonder and awe re: the moon mission? I am too. Reading this and this yesterday helped me access it.
© Adobe
In a move that will grow its oncology pipeline, Gilead Sciences is spending more than $3 billion to buy the German biotech Tubulis, the companies said Tuesday.
The deal includes an upfront payment of $3.15 billion and up to $1.85 billion more if certain milestones are reached. It also highlights both the therapeutic and commercial promise of antibody-drug conjugates, the next-generation chemotherapy treatments that the privately held Tubulis is developing.
Gilead’s latest move comes just months after it said it would acquire Arcellx in a deal worth $7.8 billion. The two companies had already been working together on a multiple myeloma CAR-T therapy that could be approved later this year. Gilead last month also announced that it was buying Ouro Therapeutics, which is focused on drugs for autoimmune disease, for up to $2.18 billion.
Continue to STAT+ to read the full story…
© Justin Sullivan/Getty Images
The failure mode for enterprise AI in 2026 is not what most people expected. It is not that the models are wrong, or that agents cannot reason, or that the technology is overhyped. The failure mode is that the data feeding those systems is fragmented, inconsistently labelled, and spread across dozens of applications that were never designed to share context.
Boomi calls this the agentic AI data activation problem, and after tracking 75,000 AI agents running in production across its customer base, the company says solving it comes before everything else. That figure comes from February, when Boomi reported its strongest momentum to date: more than 30,000 customers globally, 75,000 AI agents in production, and a customer base that includes over a quarter of the Fortune 500.
Yet the consistent pattern across those deployments, according to Steve Lucas, chairman and CEO of Boomi, is that AI value only materialises once the data problem is resolved. “AI only delivers value when data is properly activated, trusted and governed first,” Lucas said when the company announced its latest platform capabilities on March 9.
Enterprise data is not missing; it exists in abundance, distributed across ERP systems, CRMs, data lakes, SaaS platforms, and legacy applications that have accumulated over decades. What is missing is the shared context that allows an AI agent to treat data from one system as reliably compatible with data from another.
An agent drawing customer records from a CRM and pricing data from an ERP may be working from conflicting definitions of what a customer or a product actually is. The outputs it produces are only as coherent as the data standards beneath them.
Boomi’s answer is Meta Hub, a central system of record announced in its March 9 platform update, designed to standardise business definitions across the enterprise and extend that context to every AI agent operating within it. The goal is to ensure agents reason from a consistent understanding of business logic rather than generating outputs based on fragmented interpretations pulled from disconnected systems.
The same release introduced real-time SAP data extraction via change data capture, addressing one of the most common integration bottlenecks in large enterprises, where SAP data is often inaccessible due to slow, manual export processes that render it effectively unavailable to AI workflows in real-time.
New governance capabilities for Snowflake Cortex agents within Boomi’s Agent Control Tower added audit trails and session logs, addressing a concern that has moved steadily up enterprise priority lists: AI agents operating as a black box, taking actions with no visible reasoning chain.
Two independent assessments in March gave Boomi external validation of its positioning. On March 16, Gartner named Boomi a Leader in its 2026 Magic Quadrant for Integration Platform as a Service–the twelfth consecutive time–and positioned it highest for Ability to Execute.
On March 31, the IDC MarketScape for Worldwide API Management named Boomi a Leader, specifically noting its AI-centric strategy that treats APIs as both the fuel and the control plane for AI workloads. The Gartner framing is pointed.
The report stated that AI-ready integration is a strategic capability that aligns architecture, integration, and governance to enable AI agents to effectively access enterprise data and operate within business processes. That framing validates the problem Boomi is addressing and signals that iPaaS platforms are now being evaluated on AI readiness rather than traditional integration capabilities alone.
By now, we are aware that the shift from pilot to production in enterprise AI is stalling in a predictable place. Organisations have models. They have agents. What many do not have is the data infrastructure that makes those agents reliable enough to trust with real business processes.
Data activation–moving data from static storage into live, governed, context-rich flows that agents can actually reason from–is one articulation of what that missing layer needs to look like. Whether that framing becomes the industry standard or gets absorbed into a broader category is a question 2026 will start to answer.
What is not in question is that the enterprises finding ROI from agentic AI are the ones that sorted the data layer first.
Boomi will be exhibiting at the AI & Big Data Expo at TechEx North America, taking place 18–19 May 2026 at the San Jose McEnery Convention Centre.
(Photo by Boomi)
See also: Autonomous AI systems depend on data governance
Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events including the Cyber Security & Cloud Expo. Click here for more information.
AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.
The post Boomi calls it “data activation” and says it’s the missing step in every AI deployment appeared first on AI News.
The Anthropic UK expansion story is less about diplomatic courtship and more about what happens when a government punishes a company for having principles. In late February, US Defence Secretary Pete Hegseth gave Anthropic CEO Dario Amodei a stark ultimatum: remove guardrails preventing Claude from being used for fully autonomous weapons and domestic mass surveillance, or face consequences.
Amodei didn’t budge. He wrote that Anthropic could not “in good conscience” grant the Pentagon’s request, arguing that some uses of AI “can undermine rather than defend democratic values.” Washington’s response was swift.
Trump directed every federal agency to immediately cease all use of Anthropic’s technology, and the Pentagon designated the company a supply chain risk, a label ordinarily reserved for adversarial foreign entities like Huawei. The US$200 million Pentagon contract was pulled.
Defence tech companies instructed employees to stop using Claude and switch to alternatives. London, watching all of this unfold, saw something different.
Staff at the UK’s Department for Science, Innovation and Technology (DSIT) have drawn up proposals for the US$380 billion company, ranging from a dual stock listing on the London Stock Exchange to an office expansion in the capital, according to multiple people with knowledge of the plans. Prime Minister Keir Starmer’s office has backed the effort, which will be put to Amodei when he visits in late May.
Anthropic already has around 200 employees in Britain and appointed former prime minister Rishi Sunak as a senior adviser last year. The infrastructure for a meaningful UK presence is already there. What the British government is now offering is an explicit signal that Anthropic’s approach to AI–built on embedded ethical constraints–is an asset, not an obstacle.
A dual listing in London, if it materialised, would give Anthropic access to European institutional investors at a moment when its domestic regulatory standing remains under active legal challenge. The Pentagon’s appeal of the court-ordered injunction blocking the supply chain designation is still before the Ninth Circuit, and the outcome remains uncertain.
The dispute has been framed largely as a legal and political fight. But its implications for global AI governance run deeper. Anthropic’s lawyers argued in court filings that Claude was not developed to be used for lethal autonomous weapons without human oversight, nor deployed to spy on US citizens, and that using the tools in these ways would represent an abuse of its technology.
US District Judge Rita Lin, who granted a preliminary injunction blocking the blacklist in March, found the government’s actions “troubling” and concluded they likely violated the law. That judicial finding matters in the UK context. Britain is positioning itself as a regulatory environment sitting between Washington’s current posture, which demands unrestricted military access, and Brussels, where the EU AI Act imposes its own constraints.
The UK government presents itself as offering a less constrained environment for AI companies than either the US or the European Union. Crucially, that pitch doesn’t ask Anthropic to abandon the guardrails it went to court to defend.
The courtship also sits alongside broader UK efforts to build domestic AI capability, including a recently announced £40 million state-backed research lab, after officials acknowledged the absence of a homegrown competitor to the leading US frontier labs.
The UK’s play for Anthropic is not happening in a vacuum. OpenAI has already committed to making London its biggest research hub outside the US. Google has anchored itself in King’s Cross since acquiring DeepMind in 2014. The race to secure frontier AI in London is already competitive, and Anthropic’s current circumstances make it the most consequential target yet.
Anthropic has been expanding internationally regardless of its domestic legal battles, including opening a Sydney office as its fourth Asia-Pacific location. The global growth strategy is already in motion. What remains to be seen is how much of it London gets to claim.
The company Washington blacklisted for having an AI ethics policy is now being actively courted by another G7 government that wants exactly that. The late May meetings with Amodei will be telling.
See Also: Anthropic selected to build government AI assistant pilot
Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events including the Cyber Security & Cloud Expo. Click here for more information.
AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.
The post Anthropic’s refusal to arm AI is exactly why the UK wants it appeared first on AI News.
An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year according to a new analysis. Advocates argue the low cost means the company should find it easier to license the drug so that low- and middle-income countries can gain easy access.
The pill, dubbed MK 8527, is currently undergoing a pair of late-stage clinical trials that are expected to determine whether the medicine can lower HIV transmission when given to people at high risk of infection. The results are due in the latter half of 2027, according to separate postings on ClinicalTrials.gov.
Already, the pill is generating considerable interest after Merck released mid-stage results last summer showing its drug holds promise. In addition to being safe and effective, the study found it could protect against infection, a form of prevention known as pre-exposure prophylaxis or PrEP, within 24 hours after being taken. Merck noted the pill works in a novel way.
Continue to STAT+ to read the full story…
© Adobe
An abdominal aortic aneurysm is a life-threatening vascular condition with limited treatment options.
Now, researchers from the University of Michigan Frankel Cardiovascular Center have identified a driving force behind the condition, opening up a potential target for new therapies. Their paper uncovering the causal link between triglycerides and abdominal aortic aneurysms won the STAT Madness 2026 popular vote.
© Kara Gavin/University of Michigan
For her new research on the brain’s plumbing system, neuroscientist Maiken Nedergaard had to hone many techniques. Among them — coaxing her lab mice into restful sleep, even as they lay on microscope beds with tiny fiberoptic wires threaded into their brains.
“It was really hard to get the mice to sleep naturally,” said Nedergaard, who spent weeks cuddling the animals in her hands, so they’d learn to feel safe. “But then we said, ‘we really want to not have them disturbed.’”
© J. Adam Fenster / University of Rochester
WASHINGTON — The Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs.
FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers.
The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. For example, many of the brand drugmakers that struck deals to lower U.S. prices also promised to increase domestic manufacturing, under the threat of tariffs.
Continue to STAT+ to read the full story…
© DREW ANGERER/AFP via Getty Images
Every year, the Genetics Society of America bestows the Elizabeth W. Jones Award for Excellence in Education, recognizing someone who has helped the public better understand the science of DNA. It’s understood to be a lifetime achievement award; past recipients tend toward retirement age with decades of work behind them and stacks of textbooks to their names.
When this year’s winner, Brian Donovan, was announced at the end of February, many geneticists and science educators found it hard to celebrate the news. Not because he’s undeserving of the honor. Far from it. But because it seemed to confirm what many feared: that Donovan’s incandescent research career was over before it had barely begun.
© Jerry McBride for STAT
About 20 years ago, I stepped on stage at one of our Geisinger town halls and looked out upon a sea of people: thousands of full-time employees at an integrated health system charged with the health and well-being of millions of Pennsylvanians.
Only a fraction of the people in that room were clinicians.
That was the first time I fully visualized the problem: We employed more people in our revenue cycle department to process bills and reconcile data than we did doctors. And we weren’t alone. It’s the same story at every health system in America, large and small, and over the past two decades, the ratio has become dramatically more disparate.
Continue to STAT+ to read the full story…
© Adobe
In medicine, we like to believe that progress is linear. That once a patient stabilizes, regains lost skills, and returns to work, the hardest part is behind them. But in addiction care, stability is fragile because the systems supporting patients are weak.
Recently, I sat with a patient who has done everything we ask of people in recovery. She has been abstinent for years. She attends visits. Her urine drug screens are consistently appropriate. She works. She parents. She plans for the future. And yet, halfway through our appointment, her voice changed, not when we discussed cravings or trauma, but when she told me her insurance premium was about to triple.
© Adobe
Login